Over the 90-day window ending February 19, 2026, Alnylam Pharmaceuticals's three dominant insider ownership positions are held by Chief Executive Officer John Maraganore (227.66K shares), Chief Executive Officer Yvonne Greenstreet (85.66K shares), Evp And Chief Financial Officer Jeffrey V. Poulton (59.80K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| John Maraganore | Chief Executive Officer | 227,663 | 23 Dec, 2021 |
| Yvonne Greenstreet | Chief Executive Officer | 85,662 | 17 Feb, 2026 |
| Jeffrey V. Poulton | Evp And Chief Financial Officer | 59,802 | 17 Feb, 2026 |
| Tolga Tanguler | Evp And Chief Commercial Officer | 31,769 | 17 Feb, 2026 |
| Pushkal Garg | Evp Chief R&D | 24,848 | 17 Feb, 2026 |
| Akshay Vaishnaw | President | 22,774 | 07 Aug, 2023 |
| Kevin Joseph Fitzgerald | Cso & Evp And Head Of Research | 21,264 | 17 Feb, 2026 |
| Michael W Bonney | 16,804 | 19 Aug, 2025 | |
| Bryan Supran | Evp And Clo And Secretary | 13,026 | 03 Oct, 2025 |
| Amy W Schulman | 11,961 | 12 May, 2025 | |
| Robert W. Hesslein | Evp And Clo And Secretary | 8,002 | 05 Mar, 2025 |
| Laurie Keating | Evp And Chief Legal Officer | 5,132 | 09 Aug, 2021 |
| Indrani Lall Franchini | Evp And Clo & Secretary | 4,133 | 29 Feb, 2024 |
| Steven M Paul | 1,000 | 05 Apr, 2022 | |
| David E I Pyott | 911 | 12 May, 2025 | |
| Margaret A Hamburg | 911 | 12 May, 2025 | |
| Dennis A Ausiello | 911 | 15 Aug, 2025 | |
| Carolyn R Bertozzi | 775 | 12 May, 2025 | |
| Colleen F Reitan | 775 | 11 Sep, 2025 | |
| Charles Elliott Sigal | 775 | 12 May, 2025 | |
| Olivier Brandicourt | 775 | 12 May, 2025 | |
| Peter N Kellogg | 775 | 12 May, 2025 | |
| Marsha Fanucci | 136 | 27 Feb, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 17 Feb, 2026 | Kevin Joseph Fitzgerald | Common Stock | D | 2,041 | $331.96 | 21,264 | D | S |
| 13 Feb, 2026 | Yvonne Greenstreet | Common Stock | D | 6,958 | $310.08 | 85,662 | D | S |
| 13 Feb, 2026 | Jeffrey V. Poulton | Common Stock | D | 2,242 | $310.08 | 59,802 | D | S |
| 13 Feb, 2026 | Pushkal Garg | Common Stock | D | 2,242 | $310.08 | 24,848 | D | S |
| 13 Feb, 2026 | Tolga Tanguler | Common Stock | D | 1,959 | $310.08 | 31,769 | D | S |
| 13 Feb, 2026 | Kevin Joseph Fitzgerald | Common Stock | D | 1,959 | $310.08 | 23,305 | D | S |
| 12 Feb, 2026 | Yvonne Greenstreet | Common Stock | A | 14,209 | $0.00 | 92,620 | D | A |
| 12 Feb, 2026 | Jeffrey V. Poulton | Common Stock | A | 4,579 | $0.00 | 62,044 | D | A |
| 12 Feb, 2026 | Pushkal Garg | Common Stock | A | 4,579 | $0.00 | 27,090 | D | A |
| 12 Feb, 2026 | Tolga Tanguler | Common Stock | A | 4,000 | $0.00 | 33,728 | D | A |
| 12 Feb, 2026 | Kevin Joseph Fitzgerald | Common Stock | A | 4,000 | $0.00 | 25,264 | D | A |
| 13 Jan, 2026 | Kevin Joseph Fitzgerald | Common Stock | D | 644 | $370.00 | 22,151 | D | S |
| 13 Jan, 2026 | Kevin Joseph Fitzgerald | Common Stock | D | 280 | $372.93 | 21,386 | D | S |
| 13 Jan, 2026 | Kevin Joseph Fitzgerald | Common Stock | D | 197 | $367.52 | 23,357 | D | S |
| 13 Jan, 2026 | Kevin Joseph Fitzgerald | Common Stock | D | 562 | $368.76 | 22,795 | D | S |
| 13 Jan, 2026 | Kevin Joseph Fitzgerald | Common Stock | D | 122 | $374.33 | 21,264 | D | S |
| 13 Jan, 2026 | Kevin Joseph Fitzgerald | Common Stock | D | 485 | $371.24 | 21,666 | D | S |
| 12 Jan, 2026 | Yvonne Greenstreet | Common Stock | D | 464 | $362.38 | 83,219 | D | S |
| 12 Jan, 2026 | Yvonne Greenstreet | Common Stock | D | 537 | $359.14 | 85,287 | D | S |
| 12 Jan, 2026 | Yvonne Greenstreet | Common Stock | D | 88 | $374.44 | 78,623 | D | S |